New release LIPECELTE® trabectedin

23/12/2024

Introducing LIPECELTE® Trabectedin: A New Addition to Our Oncology Line

At Bioprofarma Bagó, we reaffirm our dedication to patient care with the launch of LIPECELTE® trabectedin, approved by ANMAT for the treatment of:

– Advanced soft tissue sarcoma (STS) in adult patients who have failed anthracycline and ifosfamide treatment or are not candidates for these therapies.
– Platinum-sensitive recurrent ovarian cancer, in combination with pegylated liposomal doxorubicin (PLD).

LIPECELTE® is available in the following presentation:

– 1 mg vial (single-unit package)

With this new launch, Bioprofarma Bagó solidifies its commitment to healthcare professionals and patients, providing innovative, high-quality solutions that make a meaningful difference in patients’ lives.

 

Bioprofarma Bagó
Working in the present, thinking the future.

Bioprofarma Bagó Announces In-Licensing Exclusive Partnership with Polaris Pharmaceuticals to introduce ADI-PEG20 (ADZODI®), an innovative First in class arginine degradation platform for hard-to-treat cancers in Argentina and other LATAM markets.

Buenos Aires, Argentina – Bioprofarma Bagó (a fully owned subsidiary of GRUPO EMPRESARIAL BAGO), today announced an exclusive licensing agreement with Polaris, a renowned American pharmaceutical company, to introduce ADI-PEG20 (ADZODI®), a novel treatment for Malignant Pleural Mesothelioma (MPM) to the LATAM. This partnership is set to improve the treatment landscape by delivering innovative therapeutic […]

(Español) Jornada de Uro Oncología FUCDIM

Sorry, this entry is only available in European Spanish.

(Español) Jornada URO ONCOSESSIONS V

Sorry, this entry is only available in European Spanish.